Clinical Trial Update: Omega-3 Fatty Acid Treatment in Multiple Sclerosis [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial evaluating omega-3 fatty acid treatment for relapsing-remitting multiple sclerosis has completed its Phase 2 and Phase 3 stages.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Omega-3 fatty acids (omega-3 fatty acids)

Snippet

Sponsor: Haukeland University Hospital | Conditions: Relapsing-Remitting Multiple Sclerosis | Phase 2, Phase 3 | Status: COMPLETED